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Background: Epidemiological studies focusing
on first-ever seizures have been carried out mainly
on community based populations. However, since
hospital populations may display varying clinical
features, we prospectively analysed patients with
first-ever seizure in a hospital based community to
evaluate prognosis and the role of complementary
investigations in the decision to administer
antiepileptic drugs (AED). 
Methods: Over one year, we recruited 177 con-
secutive adult patients with a first seizure acutely
evaluated in our hospital. During six months’ fol-
low-up data relating to AED treatment, recur-
rence of seizures and death were collected for each
patient.
Results: Neurological examination was abnor-
mal in 72.3%, neuroimaging in 54.8% and bio-
chemical tests in 57.1%. Electroencephalogram
(EEG) showed epileptiform features in 33.9%.
Toxicity represented the most common aetiology.
AED was prescribed in 51% of patients. Seizure
recurrence at six months involved 31.6% of pa-
tients completing the follow-up; mortality was
17.8%. Statistical analysis showed that brain CT,
EEG and neurological examination are indepen-
dent predictive factors for AED administration,
but only CT scan is associated with outcome.
Conclusions: Patients evaluated acutely for first-
ever seizure in a hospital setting have severe un-
derlying clinical conditions apparently related to
their relatively poor prognosis. Neuroimaging
represents the most important paraclinical test 
in predicting both treatment administration and 
outcome. 
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Epilepsy, defined as a condition typified by
seizure recurrence, is a common neurological dis-
order with a prevalence of 0.4–1% in the general
population [1] and has a major social and economic
impact. The risk of experiencing a single seizure
during one’s lifetime is estimated at 5–10% [2, 3].
The annual incidence of seizures in adults ranges
from 40–84 per 100 000 persons in developed
countries [1, 4].
Several prospective studies have investigated
the incidence of first-ever seizure in adult life and
related aetiologies [5–10], chiefly in community
based cohorts [6–10]. Others have considered only
outpatients referred to the emergency unit or out-
patient clinic [5, 11, 12]. Data on recurrence after
the initial incident are of great importance in
defining the population at risk of developing
epilepsy. They are contradictory, ranging from
23–71% in the literature [13–24]. When to initi-
ate treatment with antiepileptic drugs (AED) re-
mains a major unresolved issue. Some authors
suggest that prompt treatment of the first seizure
with AED leads to a significant reduction in
seizure recurrence [21, 22], but this assumption has
been questioned by others [20]. Moreover, there is
still a lack of consensus concerning the necessary
diagnostic workup of first seizure in an emergency
setting.
As far as we are aware there are no studies
specifically focusing on a hospital-based cohort
including outpatients referred  to the emergency
department and inpatients. We postulated that
clinical features and prognosis of patients evalu-
ated acutely for first seizure in a hospital setting
would differ from those in community based co-
horts. The aim of this survey was to prospectively
analyse patients with a first-ever seizure in a hos-
pital based population, to evaluate prognosis and
the role of complementary investigations (i.e. neu-
rological examination, EEG, laboratory investiga-
tions, neuroimaging).
Summary
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Our study was conducted at the University Hospital
of Lausanne, Switzerland, a tertiary reference centre
serving a population area of 1’000’000, and a primary
reference centre for the city (urban population approx.
200’000). Over one year, from 1 June 2002 to 31 May
2003, we prospectively collected patients diagnosed with
a recent seizure event. Patients were included in the study
only if this was their first-ever seizure episode, they were
over the age of 16 and the acute evaluation occurred in our
hospital (i.e., emergency department, intensive care de-
partments, other inpatient departments including neurolo-
gy). Subjects with anoxic encephalopathy and patients
referred to our outpatient clinic after evaluation for first
seizure elsewhere were excluded from the study. 
Each patient was given a standard medical and neu-
rological examination, haematological and biochemical
screening tests (including serum electrolytes, liver and
kidney function tests, glucose, creatinine kinase and C-re-
active protein), and 21-lead waking EEG according to the
international 10–20 system. Patients underwent brain CT
or MRI scan, unless relatively contraindicated (i.e., if id-
iopathic generalized epilepsy in a young patient was very
likely according to history and EEG). All tests were per-
formed within 12 hours of clinical evaluation. Diagnosis
of seizure type was according to the ILAE classification
[29] taking into account history, clinical features and an-
cillary tests. 
Several previous studies have divided seizures into
provoked and unprovoked [29], the former supposedly in-
volving a lesser likelihood of recurrence [7, 9, 10, 24]. In
our view, however, this classification may cause confusion
when facing first-ever seizures: a first seizure elicited by
an as yet undiagnosed tumour, for example, may be clas-
sified as provoked [29]; it would nevertheless be hazardous
not to administer AED, at least for some weeks. Similar
considerations apply to some extent to first seizures re-
lated to severe head trauma, CNS infections and possibly
stroke, but not to transient metabolic dysfunction, with-
drawal or intoxication. In fact, in a previous study mortali-
ty did not differ between patients with provoked or
unprovoked seizures, and one-third of seizure relapses
occurred after unprovoked seizures [24]. To investigate
this concern, we classified seizure aetiologies in a descrip-
tive manner and compared this classification with the
“classical” one.
One of the participating neurologists initiated AED
treatment when the likelihood of seizure recurrence was
felt to be important. If the risk of recurrence was consid-
ered to be low, patients received no treatment or transi-
tory benzodiazepine therapy.
Data on demographics (age, sex), seizure type, 
suspected aetiology, biochemical tests, emergency EEG, 
neurological exam, neuroimaging results and treatment
prescribed were collected for each patient. Six months
after enrolment, through the records of our outpatient
clinic and structured questionnaires addressed to general
practitioners or neurologists working outside the hospital,
we assessed AED treatment and incidence of recurrent
seizures as primary endpoints, and death as secondary 
endpoint. Treatment at the end of the follow-up period
was compared with treatment strategy decided acutely.
Statistical analysis was performed by means of uni-
variate analysis (c2 test with Yates continuity correction;
unpaired t-test) for the association of complementary
investigations with outcome and the relationship of
aetiological classification and outcome; and multivariate
analysis (logistic regression) for the association between
complementary investigations and the decision to treat.
Cutoff for significance was set at P <0.05.
Methods
Results 
Of 179 patients diagnosed with a first-ever
seizure evaluated at our hospital, two with  anoxic
encephalopathy were excluded from the study. 
Of the remaining 177, 108 (61%) were males and
69 (39%) females. The mean age was 52.92 ± 17.76
(range 16–100 yrs). Age distribution is shown in
figure 1. 
Seizure types were found as follows: 106 (60%)
generalised, 29 (16%) complex partial, 14 (8%)
simple partial, 26 (15%) partial secondarily genera-
lised and 2 (1%) generalised status epilepticus. Fig-
ure 2 represents the occurrence of first seizures
along the period of our study, showing a peak
incidence at the end of the year both for episodes
related to toxicity and other aetiologies.
The neurological examination was abnormal
in 128 patients (72.3%). An electroencephalogram
(EEG) was performed in all patients and found 
to be abnormal in 137 (77.4%). 60 (corresponding
to 33.9% of the total) showed epileptiform dis-
charges, whereas 77 (43.5% of the total) showed
only unspecific changes chiefly consisting of 
generalised or focal slowing. 
172 patients underwent cerebral CT scan or
(exceptionally) MRI; neuroimaging was abnormal
in 99 (54.8%). The CT scan was not performed in
five subjects: one died shortly after the seizure, one
was diagnosed with idiopathic generalised epilepsy
after the EEG (thus not fulfilling the criteria for
CT), one left hospital before having the CT, and
in the case of the last two there was a protocol vi-
olation during the weekend.
In 101 patients (57.1%) laboratory tests
showed at least one abnormality potentially related
to the seizure aetiology or resulting from seizures
Age distribution (yrs)
0
5
10
15
20
25
30
35
16–20 21–30 31–40 41–50 51–60 61–70 71–80  >81
Age in yrs
N
u
m
b
er
 o
f 
p
at
ie
n
ts
Men
Women
Total
Figure 1
Age distribution 
for occurrence 
of first seizure.
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(electrolyte abnormality, hypo- or severe nonke-
totic hyperglycaemia, significant urinary or he-
patic enzyme disturbance).
Figure 3 shows aetiologies established in the
acute phase. The most common causes were toxi-
city in 43 patients (24.3%) (illicit drug or benzodi-
azepines (BDZ) withdrawal; alcohol withdrawal or
intoxication or both: 17 of these were exclusively
BDZ abusers, the others were abusing more than
one substance); cerebrovascular disorders in 29 pa-
tients (16.4%): ischaemic stroke (16), subdural
haematoma (5), haemorrhagic stroke (4), arteri-
ovenous malformation (3), subarachnoid hae-
matoma (1): multiple causes (2 or more aeti-
ologies) in 24 (13.6%); idiopathic/cryptogenic in
23 (13%); head trauma in 19 (10.7%). Within 
the most common aetiology (toxicity), 69.8% of
patients were males and the type of seizure was
generalised in 77%, complex partial in 16% and
partial secondarily generalised in 7%. 
The risk of immediate/early seizures and late
seizures after stroke and head trauma is shown in
table 1.
Table 2 summarises the two most common
agerelated aetiologies.
The drug management protocol assessed at
the end of the first hospitalisation was as follows:
86 patients (49%) were not given AED (but in
many cases received transient BDZ), 69 (39%)
received AED monotherapy and 22 (12%) AED
polytherapy.
Assessment at six months was possible in 152
patients (85.9%) and 25 (14.1%) were lost to fol-
low-up. Seizure recurred in 48/152 subjects
(31.6% of patients evaluated). The commonest
aetiologies associated with recurrence were cere-
brovascular disorders in 9 (18.8%), multiple causes
in 8 (16.6%), neoplasia in 7 (14.6%), trauma in 
6 (12.5%), and CNS infection in 6 (12.5%). At six
months, 70.8% of the 48 patients were under AED
therapy. 27 patients died, ten having experienced
at least one recurrence, and 19 on AED therapy
(70.4%). The commonest seizure aetiologies 
associated with death were cerebrovascular disor-
ders in 8 (29.6%), multiple causes in 5 (18.5%) and
neoplasia in 3 (11.1%). Table 3 shows the treat-
ment at 6 months and illustrates the fact that at 
6 months most of our subjects were treated as at
the beginning of the study, except for polytherapy
which tended to be less frequent at follow-up. This
shows that there is a tendency to simplify treat-
ment over time whenever possible.
Frequency of seizure recurrence at six months
was 16.3% in patients who received no treatment
acutely (86), 36.2% in patients who received AED
monotherapy, and 40.9% in those on an AED
polytherapy regimen. Subjects on AED were likely
to have a recurrence or die; conversely, they were
less likely to be lost to follow-up (figure 4). 
Table 4 shows the rate of normal complemen-
tary examinations depending on the final outcome
(patients who died after a seizure recurrence,
considered a primary outcome, are included in the
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Aetiologies 
of first seizure.
Immediate/early seizures (<1 week) Late seizures (>1 week)
Total stroke (20) 7/20 (35%) 13/20 (65%)
Recurrence Death Recurrence Death
2/7 (29%) 4/7 (57%) 5/13 (38%) 3/13 (23%)
Total head trauma (19) 13/19 (68.4%) 6/19 (31.6%)
Recurrence Death Recurrence Death
4/13 (30.8%) 1/13 (7.7%) 2/6 (33.3%) 1/6 (16.7%)
Table 1
Risk of seizures following ischaemic and haemorrhagic stroke and following head
trauma (as single aetiology).
1st most common aetiology 2nd most common aetiology
<20 yrs (6) Trauma (3) Idiopathic (2)
21–30 yrs (24) Toxicity (7) Idiopathic (5)
31–40 yrs (29) Toxicity (9) Multiple (6)
41–50 yrs (28) Toxicity (10) Cerebrovascular (5)
51–60 yrs (23) Cerebrovascular (7) Toxicity (7)
61–70 yrs (22) Multiple (4) Toxicity (4)
71–80 yrs (29) Cerebrovascular (7) Trauma (6)
>81 yrs (16) Cerebrovascular (5) Multiple (3)
Table 2
2 most common aetiologies as per relative importance and in relation to patient 
age (absolute number in parenthesis).
S W I S S  M E D  W K LY 2 0 0 4 ; 1 3 4 : 5 8 6 – 5 9 2  ·  w w w. s m w. c h 589
first column). Table 5 presents the relationship be-
tween normal complementary examinations and
the decision to administer AED treatment at study
enrolment. Table 6 shows the distribution of aeti-
ologies according to the international definition
[29], with its relationship to recurrence and death,
for the 152 patients who completed the follow-up.
Table 3
Treatment and fol-
low-up at 6 months
in relation to chosen
treatment at study
enrolment.
Treatment at 6 months
Without drugs / Monotherapy Polytherapy Death Drop-out
BDZ alone
Treatment Without drugs/BDZ alone (86) 50 10 0 8 18
at enrolment Monotherapy (69) 6 40 4 14 5
Polytherapy (22) 2 12 1 5 2
A. Recurrence (48) B. Death (17) C. Patients alive without  Univariate analysis
at 6 months at 6 months (without recurrence) recurrence (87) at 6 months (A+B vs. C)
CT 14/48 3/17 47/87 P = 0.001, c2 = 10.738*
EEG 32/48 10/17 57/87 P = 0.908, c2 = 0.013
Neurostatus 8/48 1/17 23/87 P = 0.092, c2 = 2.831
Laboratory 21/48 5/17 41/87 P = 0.477, c2 = 0.504
* significant
Table 4
Rate of  normal com-
plementary examina-
tions at D0 (day of
the first seizure) di-
vided by recurrence,
death and absence 
of recurrence at six
months’ follow-up.
The table includes
only patients who
completed follow-up.
Note: the 5 CT not
performed were
considered normal
CT scans.
A. No therapy B. Monotherapy C. Polytherapy Univariate Multivariate 
(86) (69) (22) analysis analysis
(A vs. B+C)
CT 62/86 13/69 5/22 P = 0.0001, c2 = 46.761* P = 0.00001; 
OR = 12.03 (3.93–36.86)*
EEG 70/86 40/69 7/22 P = 0.0001, c2 = 16.158 * P = 0.001; 
OR = 8.08 (2.23–28.45)*
Neurostatus 35/86 11/69 3/22 P = 0.0003, c2 = 12.915 * P = 0.0001; 
OR = 3.78 (1.13–12.65)*
Laboratory 32/86 36/69 8/22 P = 0.1780, c2 = 1.809 P = 0.97; 
OR = 0.98 (0.35–2.74)
* significant
Table 5
Relationship between
normal complemen-
tary examinations
and treatment deci-
sion at enrolment.
The 5 CT not per-
formed were con-
sidered  normal CT 
scans. OR = odds
ratio (95% confidence
Interval).
Discussion
This series differs from previous studies for
two principal reasons. First, in contrast to previous
epidemiological studies it focused on a hospital
based cohort, excluding outpatients referred after
the acute diagnostic work-up. Second, the follow-
up period is shorter than in other series due to the
relatively high mortality and drop-out rate.
Our survey confirms that males are more likely
to come to medical attention for seizures, as pre-
viously shown in several epidemiological studies
[1, 5, 9, 10]. This is probably related to males’
higher rate of seizure related to drug (69.8%) or
alcohol intoxication (83.7%), especially in the
31–40 age group. The age distribution does not
show a clear maximum, unlike community cohorts
[9], a fact which probably reflects patient selection
in our population. The minima corresponding to
the 16–20 and over-80 age groups are probably
related to the prevalence of those subpopulations
in our hospital.
Incidence fluctuation during the year is not
solely related to toxic-metabolic aetiologies, since
seizures related to other causes  also exhibit
marked variability paralleling theirs. We postulate
that other variables, such as psychological, infec-
tious, or possibly meteorological, may account for
the peak in midwinter.
Overall, 60% of our seizures were generalised,
24% partial (simple and complex), 15% partial se-
condarily generalised and 1% status epilepticus.
Retrospectively, 48% of the patients with genera-
lised seizures had a focal lesion. The high propor-
tion of generalised seizures may be explicable by
the lack of precision in the description of the
seizure, resulting in overestimate of generalised
seizures [1, 30]. This is illustrated in the divergent
rates found in previous studies (generalised
seizures ranging between 39% and 68%) [5, 6, 9],
and shows that even when carefully and prospec-
tively assessed, as in our case, the exact history may
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be difficult to obtain. On the other hand, one may
postulate that patients experiencing simple partial
seizures are less likely to come to medical attention
acutely, thus possibly resulting in a referral  bias. 
The aetiology could be established acutely in
87% of our patients. The low rate of idiopathic
seizures (13%) differs from data from other stud-
ies [5, 8, 9, 12] ranging from 23.9–40%, and can
be explained by the extensive work-up and
prospective design of our series. Toxicity, espe-
cially alcohol-related, is the most common cause,
and cerebrovascular disorders are the second most
important aetiology, especially in older subjects.
These trends are similar to previous reports [4–6,
31–34].
Some studies have found that CT is essential
in the evaluation of first seizure, since structural le-
sions are found in 26–37% of patients [5, 35, 36].
Others concluded that CT, although useful in se-
lected patients, should not be used indiscrimi-
nately as a part of a standard evaluation [11, 32, 37],
or does not predict outcome [24]. In our series,
neuroimaging was abnormal in 54.8% of cases, a
fact which in our opinion highlights the impor-
tance of this investigation. The incidence of abnor-
mality is higher than previously reported, proba-
bly owing to our patients’ underlying general
condition. CT scan was the only test related to
both the outcome and the decision to treat, being
statistically significant in uni- or multivariate
analysis. 
Many previous studies point to the fact that the
EEG is an important aid to evaluation of seizure
patients [4, 5, 38, 39], showing epileptiform activ-
ity in 21–32.9% [5, 38]. Moreover, some studies
have shown that the EEG is an important predic-
tive factor for seizure recurrence [4, 20, 24, 37, 40,
E. Beghi, personal communication]. For other au-
thors the EEG is unnecessary and has no influence
on the management of epileptic patients [11, 31,
41]. Since in the UK there is a long waiting list for
EEG in most units, physicians are obliged to mana-
ge acute seizures without an EEG [31]. In our
study, 77.4% of patients had an abnormal EEG, 
including 33.9% with epileptiform discharges, a 
figure in line with the published literature. In 
statistical analysis, a normal EEG was  associated
with the decision not to treat, but not with out-
come.
Neurological examinations were, surprisingly,
found to be abnormal in the majority of our pa-
tients. This contrasts with previously published
data [5, 12]. The discrepancy is probably related 
to two factors: first, we scored the neurological 
examination as “abnormal” in cases where both
focal and nonfocal signs occurred. Second, as dis-
cussed before, our subjects may reflect a relatively
morbid, hospital-based population. Normal neu-
rological examination was statistically associated
with the decision not to treat, but not with out-
come.
Previous studies suggest that haematological
and biochemical screening tests are of minimal or
no value in the evaluation of patients with seizures
[5, 11, 12, 35, 37]. Our results confirm that labo-
ratory tests are not predictive of outcome or of the
decision to administer AED. However, in our
series biochemical abnormalities potentially re-
lated to seizure aetiology were detected in 57.1%.
As these are potentially treatable, we suggest that
biochemical screening should be part of the stan-
dard work-up. Moreover, the high incidence in our
series compared to the data reported in other
studies (4.9% [12]) again underlines our patients’
pre-existent morbidity. 
Mortality has been shown to be higher in
newly diagnosed patients than in the standard 
population, especially during the first 2 years after
diagnosis, and to be related to the underlying
pathology [13, 25–28], as shown in our study (es-
pecially pneumonia, neoplasia and stroke). Mor-
tality at one year has been found to be 14–18.4%
[13, 26] and at ten years 36.4% [25]. Another study
reported mortality of 26% in patients aged under
20 for a cohort of 1355 patients with a mean fol-
low-up of 28 years [28]. Within our six months’
follow-up period, 17.8% of the patients died, a 
figure apparently    higher than previous data. This
again is probably related to our patients’ underly-
ing clinical condition.
Published studies report big differences in
prognosis after first seizures [13–23]. The varia-
tion found in recurrence rates appears to be due 
to methodological differences or to study popu-
lations’ characteristics (retrospective versus
prospective design, selection of patients, length of
time before study entry and of follow-up). The risk
of relapse has been reported to vary between 46%
at six months [14], 23–71% at two years [E. Beghi,
personal communication; 22], and 29–78% of pa-
tients at three years [11, 14, 18, 20, 23, 35]. More
than 50% of patients who have a recurrence will
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Figure 4
Percentage of
patients with recur-
rence, death or drop-
out at six months 
in relation to AED
treatment. prescribed
acutely.
A. Provoked (94) B. Unprovoked C. Unprovoked D. Idiopathic/ A vs. B+C D vs. B+C
nonprogressive (26) progressive (13) cryptogenic (19)
Recurrence (48 patients) 32/94 = 34% 8/26 = 31% 6/13 = 46% 2/19 = 11% 0.839 0.043*
Death (27 patients) 16/94 = 17% 5/26 = 19% 4/13 = 31% 2/19 = 11% 0.420 0.260
Unpaired t-test (* = significant)
Table 6
Relationship between
aetiologies according
to international defi-
nition [29] and recur-
rence and death, for
the 152 patients who
completed follow-up. 
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do so within 6 months [11], which corresponds to
our follow-up period. The most important predic-
tors of seizure recurrence are apparently related to
the underlying aetiology and the result of the EEG
[37], as well as to the number of seizures in the first
six months [13]. In our survey, seizure recurred in
48 patients (31.6% of patients completing the fol-
low-up), which is in line with published data. Pre-
viously described causative factors associated with
recurrence are the presence of brain lesions, neu-
ropsychiatric handicaps, poor compliance, stroke,
head trauma and alcohol consumption [15, 18, 22].
The last mentioned 3 aetiologies alone resulted in
40% recurrence within 12 months [18]. In our
study, relapse was due mainly to cerebrovascular
disorders, neoplasia, trauma and CNS infection. It
is noteworthy that toxicity – representing our most
frequent aetiology – was not associated with a
major risk of recurrence. It is generally accepted
that seizure recurrence in the setting of sympto-
matic epilepsy is more likely to occur after late
seizures than after early ones. However, our results
show that this tendency was only seen after stroke,
but not after brain trauma (table 1). 
A classification focusing on provoked/unpro-
voked/idiopathic-cryptogenic aetiologies seems to
have little practical significance in this setting
(apart from the latter group, which statistically has
a marginally better prognosis for recurrence). This
is probably related to the concerns described in the
Methods section, and especially to the fact that 
in our survey aetiologies were determined at 
enrolment, since previous studies show not incon-
siderable reclassification in some instances [24]. 
Some papers have supported a beneficial role
for early treatment with AED in reducing the risk
of relapse [15, 19, 21, E. Beghi, personal commu-
nication; 42]. Conversely, evidence against starting
AED treatment after a first seizure is provided by
non-randomised studies [11, 14, 20]. Other au-
thors argue that treatment appears to reduce short-
term relapse but is apparently ineffective in regard
to the chance of long-term remission [E. Beghi,
personal communication; 24, 43]. We observed a
greater likelihood of death and seizure recurrence
associated with AED treatment (figure 4), proba-
bly reflecting the severity of the underlying patholo-
gy. Conversely, the major drop-out rate of pa-
tients without treatment is probably related to
their good outcome.
In conclusion, our study shows that patients
evaluated on admission for an first seizure in a hos-
pital setting have different clinical characteristics
from community based cohorts. The high ratios of
abnormal neurological findings, neuroradiological
imaging and laboratory tests, associated with the
high mortality rate, underscore the fact that these
patients tend to have serious underlying condi-
tions. Hence, in our view, an extensive clinical
work-up appears to be reasonable for patients in
this setting. Statistical analysis shows that brain
imaging, EEG and neurological examination rep-
resent an independent predictive factor for AED
treatment, whereas only neuroimaging is associ-
ated with outcome in univariate analysis. Labora-
tory investigations were found to be significantly
linked to neither treatment administration nor
outcome. Treatment administration appears to be
associated with the risk of a bad outcome (seizure
recurrence or death): the design of this observa-
tional study precludes analysis of treatment effi-
cacy, but it is likely that in many patients the deci-
sion to administer AED reflects the gravity of their
underlying clinical condition. 
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